Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? | Wiklund Genome Medicine 2010 2 45 http content 2 7 45 Genome Medicine REVIEW Prostate cancer genomics can we distinguish between indolent and fatal disease using genetic markers Fredrik Wiklund Abstract Prostate cancer is one of the most heritable cancers in men and recent genome-wide association studies have revealed numerous genetic variants associated with disease. The risk variants identified using casecontrol designs that compared unaffected individuals with all types of patients with prostate cancer show little or no ability to discriminate between indolent and fatal forms of this disease. This suggests different genetic components are involved in the initiation as compared with the prognosis of prostate cancer. Future studies contrasting patients with more and less aggressive disease and exploring association with disease progression and prognosis should be more effective in detecting genetic risk factors for prostate cancer outcome. Prostate cancer Prostate cancer constitutes a major health burden being the most common non-cutaneous malignancy among men in developed countries. In 2007 almost 800 000 new cases of prostate cancer and 250 000 deaths from this disease were estimated to have occurred worldwide 1 . The highest incidence of prostate cancer is observed in the USA with 192 280 new cases and 27 360 deaths expected in 2009 thereby being the second most common cause of cancer-related death 2 . Prostate cancer is a heterogeneous disease and its natural history is not completely understood. Early autopsy studies have shown a high prevalence of clinically undetected prostate cancer at time of death. In the USA more than one in three men over 50 years of age had histologic evidence of prostate cancer at autopsy and this prevalence was observed to Correspondence Department of Medical Epidemiology and Biostatistics Karolinska Institutet Bos 281 1 71 77 Stockholm Sweden 2 BioMed Central 2010 BioMed Central Ltd increase
